These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 23649488)

  • 1. Childbirth delay may reduce risk of an aggressive breast cancer.
    Printz C
    Cancer; 2013 May; 119(10):1767. PubMed ID: 23649488
    [No Abstract]   [Full Text] [Related]  

  • 2. Triple negative endometrial cancer may be more sensitive to platinum based chemotherapy.
    Altundag O; Dursun P; Roach EC; Altundag K
    J BUON; 2013; 18(1):289. PubMed ID: 23613418
    [No Abstract]   [Full Text] [Related]  

  • 3. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High incidence of triple-negative tumors in sub-saharan Africa: a prospective study of breast cancer characteristics and risk factors in Malian women seen in a Bamako university hospital.
    Ly M; Antoine M; Dembélé AK; Levy P; Rodenas A; Touré BA; Badiaga Y; Dembélé BK; Bagayogo DC; Diallo YL; Koné AA; Callard P; Bernaudin JF; Diallo DA
    Oncology; 2012; 83(5):257-63. PubMed ID: 22964749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Biological features of breast cancer in patients under 35].
    Damenia AO; Turkevich EA; Semiglazov VF; Kochetova IA; Gurbanov SS; Bit-Sava EM; Efimenko AV
    Vopr Onkol; 2007; 53(6):674-6. PubMed ID: 18416136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving outcomes for patients with hormone receptor-positive breast cancer: back to the drawing board.
    Ellis MJ
    J Natl Cancer Inst; 2008 Feb; 100(3):159-61. PubMed ID: 18230793
    [No Abstract]   [Full Text] [Related]  

  • 7. Is breast conservation therapy superior to mastectomy for women with triple-negative breast cancers?
    Pignol JP; Rakovitch E; Olivotto IA
    J Clin Oncol; 2011 Jul; 29(21):2841-3. PubMed ID: 21670459
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical-biological meaning of progesterone receptor status in 118 estrogen receptor positive infiltrating ductal carcinomas of the breast in post-menopausal women].
    Ruibal A; Schneider J; Arias J; del Río MC; Núnez MJ; Tejerina A
    Rev Esp Med Nucl; 2000 Jun; 19(3):244-6. PubMed ID: 11062090
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pathologic diagnosis and histopathology record of breast cancer].
    Cserni G; Francz M; Járay B; Kálmán E; Kovács I; Kulka J; Orosz Z; Udvarhelyi N; Vass L
    Magy Onkol; 2010 Sep; 54(3):217-26. PubMed ID: 20870599
    [No Abstract]   [Full Text] [Related]  

  • 10. Signaling pathways in early onset sporadic breast cancer of patients in Indonesia.
    Sutandyo N; Suzanna E; Haryono SJ; Reksodiputro AH
    Acta Med Indones; 2008 Jul; 40(3):139-45. PubMed ID: 18838752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High prevalence of HER-2/neu overexpression among Iranian women with breast cancer: true or false?
    Saatee S; Afrakhteh M; Sadrolhefazi B
    Breast J; 2006; 12(5):499-501. PubMed ID: 16958978
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pharmaceutical therapy of breast cancer].
    Láng I; Kahán Z; Pintér T; Dank M; Boér K; Pajkos G; Faluhelyi Z; Pikó B; Eckhardt S; Horváth Z
    Magy Onkol; 2010 Sep; 54(3):237-54. PubMed ID: 20870601
    [No Abstract]   [Full Text] [Related]  

  • 13. Prognostic and predictive factors of invasive ductal breast carcinomas.
    Lialiaris TS; Georgiou G; Sivridis E; Kareli D; Tripsiannis G; Papageorgiou A; Chrisafi S; Kritsi Z; Giatromanolaki A
    J BUON; 2010; 15(1):79-88. PubMed ID: 20414932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The reliability of rabbit monoclonal antibodies in the immunohistochemical assessment of estrogen receptors, progesterone receptors, and HER2 in human breast carcinomas.
    Rhodes A; Sarson J; Assam EE; Dean SJ; Cribb EC; Parker A
    Am J Clin Pathol; 2010 Oct; 134(4):621-32. PubMed ID: 20855644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognosis prediction of S-phase fraction and p53, c-erbB-2, estrogen receptor, progesterone receptor in axillary node-negative breast cancer].
    Zhang S; Yuan Y; Wang X
    Zhonghua Wai Ke Za Zhi; 1997 Aug; 35(8):475-7. PubMed ID: 10678068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunologic differences of triple-negative and luminal A breast cancer].
    Mel'nikov DIu; Pushina IV; Lagereva IuG; Beĭkin IaB; Ivanova IIu
    Vopr Onkol; 2013; 59(3):390-2. PubMed ID: 23909044
    [No Abstract]   [Full Text] [Related]  

  • 17. Distinctive biology of pleomorphic lobular carcinoma of the breast.
    Moe RE; Anderson BO
    J Surg Oncol; 2005 May; 90(2):47-50. PubMed ID: 15844193
    [No Abstract]   [Full Text] [Related]  

  • 18. [Prognostic and predictive factors in breast cancer].
    Bozhok AA; Semiglazov VF; Semiglazov VV; Arzumanov AS; Klettsel' AE
    Vopr Onkol; 2005; 51(4):434-43. PubMed ID: 16308974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor cells and biomarkers: implications for personalized targeted treatments for metastatic breast cancer.
    Reuben JM; Lee BN; Li C; Gao H; Broglio KR; Valero V; Jackson SA; Ueno NT; Krishnamurthy S; Hortobagyi GN; Cristofanilli M
    Breast J; 2010; 16(3):327-30. PubMed ID: 20408820
    [No Abstract]   [Full Text] [Related]  

  • 20. [Which biomarkers can we use?].
    Nogi H; Uchida K; Kobayashi T
    Nihon Rinsho; 2012 May; 70(5):816-20. PubMed ID: 22620006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.